February’s top stories: Takeda’s $5.2bn acquisition, Sanofi €270m cell culture facility investment

1
With the acquisition of ARIAD, two new targeted therapies will improve Takeda’s existing oncology portfolio. Photo: courtesy of Freeimages.com / Marcin Jochimczyk.